Monte Rosa Therapeutics annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Monte Rosa Therapeutics Capital Expenditures (CapEx) Growth & History (GLUE)
Monte Rosa Therapeutics's capital expenditures (capex) was $4.7M for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.7M | $712,000 | +17.85% |
| 2024 | 2024-12-31 | $4.0M | −$15.1M | −79.06% |
| 2023 | 2023-12-31 | $19.0M | $6.1M | +47.48% |
| 2022 | 2022-12-31 | $12.9M | $3.2M | +32.67% |
| 2021 | 2021-12-31 | $9.7M | $6.3M | +187.16% |
| 2020 | 2020-12-31 | $3.4M | — | — |
Monte Rosa Therapeutics quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.7M | $3.0M | +178.64% |
| Q1 2026 | 2026-03-31 | $1.9M | $281,000 | +17.71% |
| Q4 2025 | 2025-12-31 | $767,000 | $584,000 | +319.13% |
| Q3 2025 | 2025-09-30 | $651,000 | $252,000 | +63.16% |
| Q2 2025 | 2025-06-30 | $1.7M | −$327,000 | −16.17% |
| Q1 2025 | 2025-03-31 | $1.6M | $203,000 | +14.67% |
| Q4 2024 | 2024-12-31 | $183,000 | −$1.5M | −89.17% |
| Q3 2024 | 2024-09-30 | $399,000 | −$1.3M | −75.95% |
| Q2 2024 | 2024-06-30 | $2.0M | −$4.5M | −68.95% |
| Q1 2024 | 2024-03-31 | $1.4M | −$7.8M | −84.93% |
| Q4 2023 | 2023-12-31 | $1.7M | −$5.6M | −76.77% |
| Q3 2023 | 2023-09-30 | $1.7M | $259,000 | +18.50% |
| Q2 2023 | 2023-06-30 | $6.5M | $4.0M | +155.07% |
| Q1 2023 | 2023-03-31 | $9.2M | $7.5M | +444.22% |
| Q4 2022 | 2022-12-31 | $7.3M | $4.2M | +137.69% |
| Q3 2022 | 2022-09-30 | $1.4M | −$355,000 | −20.23% |
| Q2 2022 | 2022-06-30 | $2.6M | −$148,000 | −5.48% |
| Q1 2022 | 2022-03-31 | $1.7M | −$530,000 | −23.91% |
| Q4 2021 | 2021-12-31 | $3.1M | — | — |
| Q3 2021 | 2021-09-30 | $1.8M | $825,000 | +88.71% |
| Q2 2021 | 2021-06-30 | $2.7M | — | — |
| Q1 2021 | 2021-03-31 | $2.2M | — | — |
| Q3 2020 | 2020-09-30 | $930,000 | — | — |
Monte Rosa Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Monte Rosa Therapeutics's capital expenditures (capex) increased from $3.4M to $4.7M, a change of $1.3M. The latest reported quarter, Q2 2026, shows $4.7M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗